ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

HROW vs MLTX // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Harrow Inc. (NASDAQ) VS. MoonLake Immunotherapeutics (Class A) (NASDAQ) • 15-METRIC TALLY: HROW 4 — MLTX 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HROW VS. MLTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC HROW MLTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 75.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 42.90% -35.00% +77.90 HROW /roic <GO>
EV/EBITDA & P/E Valuation 33.6x — — TIE /valuation <GO>
Free Cash Flow Yield 3.82% -18.33% +22.15 HROW /fcf-yield <GO>
Operating Margin 11.20% — — TIE /operating-margins <GO>
Net Profit Margin -1.90% — — TIE /net-margins <GO>
Revenue Growth (YoY) 36.40% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.67 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 2/9 +5.00 HROW /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.5 57.2 -7.70 MLTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.12B $1.07B $54.5M HROW /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR HROW REV MLTX REV HROW GROSS % MLTX GROSS % HROW FCF MLTX FCF
FY 2025 $272.3M $0 75.1% — $43.0M -$196.0M
FY 2024 $199.6M $0 75.3% — -$23.8M -$117.1M
FY 2023 $130.2M $0 — — $3.8M -$42.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HROW // BETA —
MLTX // BETA —